Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less pathologically advanced in their disease.
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together' Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
LVM Capital Management Loads Up on NOC, Buys 6,237 Shares in Q2 2025 LVM Capital Management bought a $3.16 million stake in Northrop Grumman last quarter.
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care.
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...' Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .
2 Cash-Producing Stocks Worth Investigating and 1 to Brush Off A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
